Cargando…
The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327742/ https://www.ncbi.nlm.nih.gov/pubmed/33626861 http://dx.doi.org/10.3324/haematol.2020.261354 |
| _version_ | 1783732158401085440 |
|---|---|
| author | Tran, Thai Hoa Nguyen, Jonathan V. Stecula, Adrian Akutagawa, Jon Moorman, Anthony V. Braun, Benjamin S. Sali, Andrej Mullighan, Charles G. Shah, Neil P. Dai, Yunfeng Devidas, Meenakshi Roberts, Kathryn G. Smith, Catherine C. Loh, Mignon L. |
| author_facet | Tran, Thai Hoa Nguyen, Jonathan V. Stecula, Adrian Akutagawa, Jon Moorman, Anthony V. Braun, Benjamin S. Sali, Andrej Mullighan, Charles G. Shah, Neil P. Dai, Yunfeng Devidas, Meenakshi Roberts, Kathryn G. Smith, Catherine C. Loh, Mignon L. |
| author_sort | Tran, Thai Hoa |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8327742 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83277422021-08-11 The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment Tran, Thai Hoa Nguyen, Jonathan V. Stecula, Adrian Akutagawa, Jon Moorman, Anthony V. Braun, Benjamin S. Sali, Andrej Mullighan, Charles G. Shah, Neil P. Dai, Yunfeng Devidas, Meenakshi Roberts, Kathryn G. Smith, Catherine C. Loh, Mignon L. Haematologica Letters to the Editor Fondazione Ferrata Storti 2021-02-25 /pmc/articles/PMC8327742/ /pubmed/33626861 http://dx.doi.org/10.3324/haematol.2020.261354 Text en Copyright© 2021 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Tran, Thai Hoa Nguyen, Jonathan V. Stecula, Adrian Akutagawa, Jon Moorman, Anthony V. Braun, Benjamin S. Sali, Andrej Mullighan, Charles G. Shah, Neil P. Dai, Yunfeng Devidas, Meenakshi Roberts, Kathryn G. Smith, Catherine C. Loh, Mignon L. The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment |
| title | The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment |
| title_full | The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment |
| title_fullStr | The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment |
| title_full_unstemmed | The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment |
| title_short | The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment |
| title_sort | ebf1-pdgfrb t681i mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327742/ https://www.ncbi.nlm.nih.gov/pubmed/33626861 http://dx.doi.org/10.3324/haematol.2020.261354 |
| work_keys_str_mv | AT tranthaihoa theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT nguyenjonathanv theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT steculaadrian theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT akutagawajon theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT moormananthonyv theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT braunbenjamins theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT saliandrej theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT mullighancharlesg theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT shahneilp theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT daiyunfeng theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT devidasmeenakshi theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT robertskathryng theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT smithcatherinec theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT lohmignonl theebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT tranthaihoa ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT nguyenjonathanv ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT steculaadrian ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT akutagawajon ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT moormananthonyv ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT braunbenjamins ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT saliandrej ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT mullighancharlesg ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT shahneilp ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT daiyunfeng ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT devidasmeenakshi ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT robertskathryng ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT smithcatherinec ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment AT lohmignonl ebf1pdgfrbt681imutationishighlyresistanttoimatinibanddasatinibinvitroanddetectableinclinicalsamplespriortotreatment |